FinTechFunding

Triad Life Sciences: Closes A$25M Funding

Triad Life Sciences Closes A$25M Funding

  • Triad Life Sciences, a Memphis, Tenn.-based biotech company, raised AUS$25m funding round
  • The convertible note placement was led by Cannacord Genuity
  • The company intends to use the funds for its US sales force expansion plans, R&D activities, and general working capital needs
  • Triad now plans to move forward with a listing on the Australian Securities Exchange (ASX) in the coming months
  • Led by CEO Russ Olsen, TriadLife Sciences is a biotech company focused on developing and commercializing biomaterials for treating complex surgical and chronic wounds
  • Triad recently received FDA clearance to market InnovaMatrix™, a next generation extracellular matrix (ECM) wound care device
Previous article
Lextegrity: Raises Additional $5M in Funding
Next article
Hive: Raises $10M in Funding
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FinTech

NextGen Nordics 2026 Strengthens Future of Money with 29 Leading Voices

A lineup of key speakers will shape discussions on financial innovation.Highlights: NextGen Nordics 2026 to feature 29 key...
FinTech

Revolut Aims to Go Public Within Two Years

The fintech prepares for a potentially significant market entry.Highlights: Revolut plans to pursue an IPO within the next...
FinTech

Mexican Neobank Plata Achieves $5 Billion Valuation

Plata rises as a leader in the Mexican fintech landscape.Highlights: Plata's valuation hits $5 billion following a successful...
FinTech

Piraeus Bank Strengthens AI Capabilities with Accenture and Anthropic Hub

New AI hub aims to enhance banking services and improve customer experiences.Highlights: Piraeus Bank launches an AI hub...